+ All Categories
Home > Documents > GSK_2011.pptx

GSK_2011.pptx

Date post: 02-Apr-2018
Category:
Upload: sandeep-chowdhury
View: 216 times
Download: 0 times
Share this document with a friend

of 20

Transcript
  • 7/27/2019 GSK_2011.pptx

    1/20

    Merchand-I

  • 7/27/2019 GSK_2011.pptx

    2/20

    Established in the year 1924 in India, it is one of theoldest pharmaceuticals company

    Headquarters in Worli, Mumbai (only registeredoffice) and 2 plants in Thane and Nashik.

    Globally it is a leading, research-based healthcareand pharmaceutical company with headquarters inLondon, United Kingdom

    Amongst the top three players in the domesticmarket

    Dr. H. B. Joshipura Chairman

    S. Khanna V.P. Finance

    Total employee strength of over 3500 people

  • 7/27/2019 GSK_2011.pptx

    3/20

    Mission: To improve the quality of human lifeby enabling people to do more, feel betterand live longer.

    Corporate Governance: Strong emphasis ontransparency, accountability and integrity

  • 7/27/2019 GSK_2011.pptx

    4/20

    Make a valuable contribution to society Improve people's lives

    Target support to selected programs that are

    innovative, sustainable Core value is to be a good corporate citizen.

    Being committed to the communities in whichit works

    Being proactive in improving the environment

  • 7/27/2019 GSK_2011.pptx

    5/20

    Dr. H. B. Joshipura - Chairman M.B. Kapadia - Senior Executive Director

    Dr. A. Banerjee - Executive Director - Technical

    R. Sequeira - Executive Director - Human Resources

    Dr. S. Joglekar - E.V.P. - Medical & Clinical Research M. K. Vasanth Kumar - E.V.P. - Supply Chain

    R. Bartaria - V. P. Pharmaceuticals

    H. M. Buch - V. P. Pharmaceuticals

    S. Khanna - V.P. - Finance

    S. Patel - V.P. - Legal & Corporate Affairs

    C. T. Renganathan - V. P. Pharmaceuticals

    S. Rajan - General Manager - Corporate Communications

  • 7/27/2019 GSK_2011.pptx

    6/20

    GSK has operations in two different segments in India: ConsumerHealthcare and Pharmaceuticals.

    Consumer Health Care: GlaxoSmithKline Consumer Health Care(GSKCH) is one of the largest players in consumer health food

    drinks industry in India. Its flagship product, Horlicks is a highlyrespected brand which is over 100 years old in India. Thecompany also manufactures: Boost

    Viva

    Maltova

    Eno

    Crocin

    Iodex

  • 7/27/2019 GSK_2011.pptx

    7/20

    Pharmaceuticals: The company is the market leader in most of thetherapeutic categories in which it operates .The GSK India product portfolioincludes prescription medicines and vaccines. Their prescription medicinesrange across therapeutic areas such as

    Anti-Infectives

    Dermatology

    Gynaecology

    Diabetes

    Cardiovascular disease

    Respiratory diseases.

    GSK also offers a range of vaccines, for the prevention

    Hepatitis A

    Hepatitis B Invasive disease caused by H

    Influenza

    Chickenpox

    Diphtheria

    Pertussis

    Tetanus

  • 7/27/2019 GSK_2011.pptx

    8/20

    GlaxoSmithKlines mass media campaign tocreate awareness about cervical cancerprevalence in India. The exercise implicitlyaimed to promote its cancer vaccine branded

    Cervarix. The advertisement displayed inprominent national dailies

  • 7/27/2019 GSK_2011.pptx

    9/20

    Ranbaxy Laboratories Dr Reddys Laboratories

    Cipla

    Piramal Healthcare Aurobindo Healthcare

    Lupin Laboratories

    Cadila Healthcare

  • 7/27/2019 GSK_2011.pptx

    10/20

    It has one wholly owned subsidiary company Biddle Sawyer Limited.

    Its parent company is

    GSK UK headquartered at London.

    Its related companies are:

    GlaxoSmithKline Pharma Ltd (Parent)Neuland Laboratories Ltd.Zhejiang Hisun Pharmaceutical Co., Ltd.Southwest Synthetic Pharmaceutical CorpZhejiang Jianfeng Group Co. Ltd

    Torrent Pharmaceuticals LimitedTorrent Pharmaceuticals Limited (P)Intervet/Schering-Plough Animal HealthPT Bristol-Myers Squibb Indonesia TbkPlethico Pharmaceuticals Limited

    http://companydatabase.org/kw/title:%22GlaxoSmithKline+Pharma+Ltd+(Parent)%22http://companydatabase.org/kw/title:%22Neuland+Laboratories+Ltd.%22http://companydatabase.org/kw/title:%22Zhejiang+Hisun+Pharmaceutical+Co.,+Ltd.%22http://companydatabase.org/kw/title:%22Southwest+Synthetic+Pharmaceutical+Corp%22http://companydatabase.org/kw/title:%22Zhejiang+Jianfeng+Group+Co.+Ltd%22http://companydatabase.org/kw/title:%22Torrent+Pharmaceuticals+Limited%22http://companydatabase.org/kw/title:%22Torrent+Pharmaceuticals+Limited+(P)%22http://companydatabase.org/kw/title:%22Intervet/Schering-Plough+Animal+Health%22http://companydatabase.org/kw/title:%22PT+Bristol-Myers+Squibb+Indonesia+Tbk%22http://companydatabase.org/kw/title:%22Plethico+Pharmaceuticals+Limited%22http://companydatabase.org/kw/title:%22Plethico+Pharmaceuticals+Limited%22http://companydatabase.org/kw/title:%22Plethico+Pharmaceuticals+Limited%22http://companydatabase.org/kw/title:%22Plethico+Pharmaceuticals+Limited%22http://companydatabase.org/kw/title:%22PT+Bristol-Myers+Squibb+Indonesia+Tbk%22http://companydatabase.org/kw/title:%22PT+Bristol-Myers+Squibb+Indonesia+Tbk%22http://companydatabase.org/kw/title:%22PT+Bristol-Myers+Squibb+Indonesia+Tbk%22http://companydatabase.org/kw/title:%22PT+Bristol-Myers+Squibb+Indonesia+Tbk%22http://companydatabase.org/kw/title:%22Intervet/Schering-Plough+Animal+Health%22http://companydatabase.org/kw/title:%22Intervet/Schering-Plough+Animal+Health%22http://companydatabase.org/kw/title:%22Intervet/Schering-Plough+Animal+Health%22http://companydatabase.org/kw/title:%22Intervet/Schering-Plough+Animal+Health%22http://companydatabase.org/kw/title:%22Torrent+Pharmaceuticals+Limited+(P)%22http://companydatabase.org/kw/title:%22Torrent+Pharmaceuticals+Limited%22http://companydatabase.org/kw/title:%22Zhejiang+Jianfeng+Group+Co.+Ltd%22http://companydatabase.org/kw/title:%22Zhejiang+Jianfeng+Group+Co.+Ltd%22http://companydatabase.org/kw/title:%22Zhejiang+Jianfeng+Group+Co.+Ltd%22http://companydatabase.org/kw/title:%22Zhejiang+Jianfeng+Group+Co.+Ltd%22http://companydatabase.org/kw/title:%22Southwest+Synthetic+Pharmaceutical+Corp%22http://companydatabase.org/kw/title:%22Zhejiang+Hisun+Pharmaceutical+Co.,+Ltd.%22http://companydatabase.org/kw/title:%22Zhejiang+Hisun+Pharmaceutical+Co.,+Ltd.%22http://companydatabase.org/kw/title:%22Zhejiang+Hisun+Pharmaceutical+Co.,+Ltd.%22http://companydatabase.org/kw/title:%22Zhejiang+Hisun+Pharmaceutical+Co.,+Ltd.%22http://companydatabase.org/kw/title:%22Neuland+Laboratories+Ltd.%22http://companydatabase.org/kw/title:%22Neuland+Laboratories+Ltd.%22http://companydatabase.org/kw/title:%22Neuland+Laboratories+Ltd.%22http://companydatabase.org/kw/title:%22GlaxoSmithKline+Pharma+Ltd+(Parent)%22http://companydatabase.org/kw/title:%22GlaxoSmithKline+Pharma+Ltd+(Parent)%22http://companydatabase.org/kw/title:%22GlaxoSmithKline+Pharma+Ltd+(Parent)%22http://companydatabase.org/kw/title:%22GlaxoSmithKline+Pharma+Ltd+(Parent)%22
  • 7/27/2019 GSK_2011.pptx

    11/20

    Financial Overview

  • 7/27/2019 GSK_2011.pptx

    12/20

    Last Quarter Ended 26th July 2011 Q2 reported sales -2%

    EPS before major restructuring* 25p

    Underlying sales growth of 5% Increased pipeline visibility and dividend of

    16p, up 7%

  • 7/27/2019 GSK_2011.pptx

    13/20

    Revenue of Rs. 2155.08 crore as against Rs. 1912.77 crore inFY09

    PAT of Rs. 563.68 Cr. as against Rs. 512.29 Cr. in FY09

    Diluted EPS of Rs. 66.55 as against Rs. 60.48in FY09Particular 22

    nd

    Sept 2011BSE 2056.60

    NSE 2040.50

    Market Cap 17321.34 Cr

    EPS 49.76

    Div 400.0%

    Face Value 10

  • 7/27/2019 GSK_2011.pptx

    14/20

    Financial Ratios Dec 10

    PBITM (%) 33.47

    Net Profit Margin% 25.05

    Current Ratio 2.94

    Interest Cover Ratio 1412.90

    Current Ratio 2.94

    Fixed Assets 6.67

  • 7/27/2019 GSK_2011.pptx

    15/20

    GSK follows the rationale that they are linked closely to the communities in whichthey operate- locally, nationally or globally. They cannot exist in isolation. All oftheiractions are focused around this feeling of being centered.

    Their stated mission statement is "To lend a helping hand to the underserved inour society through the support of women, children and the aged in the areas ofhealth and education." Implementing this philosophy in spirit, they make apositive contribution to the communities in which they operate, and invest inhealth and education programs and partnerships that aim to bring sustainableimprovements to underserved people.

    Rural projects Tribal welfare projects in Peth Taluka, Nashik, Maharashtra

    GSK India undertakes a number of Rural Development initiatives through itstrust GRAMIN AAROGYA VIKAS SANSTHA (GAVS), a Rural Health DevelopmentOrganization. GAVS is a registered public charitable trust established andpromoted by the heritage company Glaxo India in April 1997.

    Urban projects Primary Healthcare Centre in garbage dumping ground - Deonar, Mumbai

    GSK India runs a medical centre in Deonar Dumping Ground, the biggestdumping ground in Mumbai. This centre provides Primary healthcarefacilities and quality health education to the children who are rag pickers andtheir families who work in and around the dumping ground. This project isimplemented in collaboration with Niramaya Health Foundation.

  • 7/27/2019 GSK_2011.pptx

    16/20

    1919-1947 1950-1970 1970-1990 1991+

    - Trading links with

    India

    established(1919)

    - Secondarymanufacture

    commences after

    war(1947)

    -Primary production

    of vaccines begins at

    Worli (1956)

    -Registered as alimited company.

    Animal health

    products

    introduced(1968)

    - Research &

    development

    laboratory built at

    Thane(1971)

    -Biddle Sawyer

    acquisition is

    completed(1998)

    -Merger ofSmithKline Beecham

    Pharmaceuticals

    (India) Limited into

    Glaxo India

    Limited.(2001)

  • 7/27/2019 GSK_2011.pptx

    17/20

    1994-Certificate of Merit awarded to Ankleshwar Factory for 'Excellence in Energy

    Conservation' by the Federation of Gujarat Mills and Industries (FGMI) 1995-Glaxo wins "Marketing Company of the Year" award from the Institute of

    Marketing & Management (IMM)

    1995-Glaxo wins "The Analyst" award from Chartered Analyst magazine as aninvestor rewarding company.

    1995-Glaxo - Thane won the Chief Executive's Trophy for Health Safety and

    Environmental Management 1999-Winner of the 1999 IMM (Institute of Marketing and Management) Award for

    Excellence as Marketing Company (organised sector)

    1999-The company's HIV / AIDS campaign in Press wins the first prize for the best"Social Responsibility Communication", awarded by the Association of BusinessCommunicators of India (ABCI)

    1999-The Positive People Campaign entitled 'Real Friendships Don't Die with HIV'also wins the Global Award from the New York Festivals

    2004-Receives prestigious Multi Cultural Diversity Award from GlaxoSmithKlineConsumer Healthcare Limited, U.S. for the Famili Vaccines programme, selectedfrom 83 entries received from markets world-wide

  • 7/27/2019 GSK_2011.pptx

    18/20

  • 7/27/2019 GSK_2011.pptx

    19/20

    Desired QualitiesPerformance with integrity

    Entrepreneurial spirit

    Focus on innovation

    A sense of urgencyPassion for achievement

  • 7/27/2019 GSK_2011.pptx

    20/20


Recommended